Short Interest in IN8bio, Inc. (NASDAQ:INAB) Decreases By 35.1%

IN8bio, Inc. (NASDAQ:INAB) was the recipient of a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 90,842 shares, a drop of 35.1% from the August 15th total of 139,903 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily trading volume, of 55,295 shares, the short-interest ratio is currently 1.6 days.

IN8bio Trading Up 5.9%

Shares of INAB stock traded up $0.06 during trading hours on Thursday, reaching $1.07. 47,945 shares of the company’s stock were exchanged, compared to its average volume of 64,555. IN8bio has a 1 year low of $0.88 and a 1 year high of $2.73. The stock has a market cap of $10.55 million, a PE ratio of -0.66 and a beta of 0.30. The stock’s fifty day moving average price is $1.15 and its two-hundred day moving average price is $1.41.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.09. On average, equities analysts expect that IN8bio will post -1.25 EPS for the current fiscal year.

Analyst Ratings Changes

INAB has been the subject of several recent research reports. HC Wainwright restated a “buy” rating on shares of IN8bio in a report on Thursday, June 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, IN8bio currently has a consensus rating of “Hold” and an average target price of $4.00.

Institutional Trading of IN8bio

A hedge fund recently bought a new position in IN8bio stock. 683 Capital Management LLC acquired a new position in IN8bio, Inc. (NASDAQ:INAB) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 724,637 shares of the company’s stock, valued at approximately $1,696,000. 683 Capital Management LLC owned approximately 7.42% of IN8bio at the end of the most recent quarter. 92.05% of the stock is currently owned by institutional investors.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing ?? T cell therapeutic and ?? T cell engager (TCE) product candidates to address unmet medical needs. ?? T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic ?? T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.